Affymax, Inc. is a biopharmaceutical company. The company is headquartered in New York City, New York and currently employs 4 full-time employees. The company went IPO on 2006-12-15. The Company’s product OMONTYS (peginesatide) is for the treatment of anemia due to chronic kidney disease in adult patients on dialysis. OMONTYS is a synthetic, peptide-based erythropoiesis stimulating agent (ESA), designed to stimulate production of red blood cells. The firm has a collaboration to develop and commercialize peginesatide with Takeda Pharmaceutical Company Limited. In March 2012, the Food and Drug Administration (FDA) approved the Company’s product, OMONTYS.
Follow-Up Questions
Affymax Inc 'in CEO'su kimdir?
Mr. Jonathan Couchman 2014 'den beri şirketle birlikte olan Affymax Inc 'in President 'ıdır.
AFFY hissesinin fiyat performansı nasıl?
AFFY 'in mevcut fiyatı $0.0008 'dir, son işlem günde 0% decreased etti.
Affymax Inc için ana iş temaları veya sektörler nelerdir?
Affymax Inc N/A endüstrisine ait ve sektör N/A 'dir
Affymax Inc 'in piyasa değerlemesi nedir?
Affymax Inc 'in mevcut piyasa değerlemesi $29992 'dir
